Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.The results of research on the compound in mice appear in the Jan. 1 issue of Cancer Research. The article is highlighted on the cover.The compound was used for the first time in human patients with solid tumors in 2007.
